Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus

References

• Cheng YJ Imperatore G Geiss LS Secular changes in the age-specific prevalence of diabetes among US adults: 1988–2010 Diabetes Care 2013 36 9 2690 2696 23637354
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation IDF Diabetes Atlas 6th ed Brussels IDF 2013
   Google Scholar
• Centers for Disease Control and Prevention National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States Atlanta CDC 2011
   Google Scholar
• Barrett-Connor EL Cohn BA Wingard DL Edelstein SL Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study JAMA 1991 265 5 627 631 1987413
   PubMed Web of Science ®Google Scholar
• Fuller JH Shipley MJ Rose G Jarrett RJ Keen H Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study Br Med J (Clin Res Ed) 1983 287 6396 867 870
   PubMed Web of Science ®Google Scholar
• Kannel WB McGee DL Diabetes and cardiovascular disease. The Framingham study JAMA 1979 241 19 2035 2038 430798
   PubMed Web of Science ®Google Scholar
• Manson JE Colditz GA Stampfer MJ A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women Arch Intern Med 1991 151 6 1141 1147 2043016
   PubMedGoogle Scholar
• Stamler J Vaccaro O Neaton JD Wentworth D Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 1993 16 2 434 444 8432214
   PubMed Web of Science ®Google Scholar
• Haffner SM Lehto S Rönnemaa T Pyörälä K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998 339 4 229 234 9673301
   PubMed Web of Science ®Google Scholar
• Franco OH Steyerberg EW Hu FB Mackenbach J Nusselder W Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease Arch Intern Med 2007 167 11 1145 1151 17563022
   PubMedGoogle Scholar
• Behar S Boyko V Reicher-Reiss H Goldbourt U Ten-year survival after acute myocardial infarction: comparison of patients with and without diabetes. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial Am Heart J 1997 133 3 290 296 9060796
   PubMed Web of Science ®Google Scholar
• Mak KH Moliterno DJ Granger CB Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries J Am Coll Cardiol 1997 30 1 171 179 9207639
   PubMed Web of Science ®Google Scholar
• Malmberg K Yusuf S Gerstein HC Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry Circulation 2000 102 9 1014 1019 10961966
   PubMed Web of Science ®Google Scholar
• Gregg EW Cheng YJ Saydah S Trends in death rates among US adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey Diabetes Care 2012 35 6 1252 1257 22619288
   PubMed Web of Science ®Google Scholar
• Farkouh ME Boden WE Bittner V Risk factor control for coronary artery disease secondary prevention in large randomized trials J Am Coll Cardiol 2013 61 15 1607 1615 23500281
   PubMed Web of Science ®Google Scholar
• Joseph J Svartberg J Njølstad I Schirmer H Change in cardiovascular risk factors in relation to diabetes status: the Tromso Study Eur J Prev Cardiol 2012 19 3 551 557 21505026
   PubMed Web of Science ®Google Scholar
• Saydah SH Fradkin J Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes JAMA 2004 291 3 335 342 14734596
   PubMed Web of Science ®Google Scholar
• Haffner SM Pre-diabetes, insulin resistance, inflammation and CVD risk Diabetes Res Clin Pract 2003 61 Suppl 1 S9 S18 12880690
   PubMed Web of Science ®Google Scholar
• Preis SR Pencina MJ Hwang SJ Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study Circulation 2009 120 3 212 220 19581493
   PubMed Web of Science ®Google Scholar
• Helfand M Buckley DI Freeman M Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the US. Preventive Services Task Force Ann Intern Med 2009 151 7 496 507 19805772
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force Using nontraditional risk factors in coronary heart disease risk assessment: US Preventive Services Task Force recommendation statement Ann Intern Med 2009 151 7 474 482 19805770
   PubMed Web of Science ®Google Scholar
• Fonseca V Desouza C Asnani S Jialal I Nontraditional risk factors for cardiovascular disease in diabetes Endocr Rev 2004 25 1 153 175 14769830
   PubMed Web of Science ®Google Scholar
• Resnick HE Howard BV Diabetes and cardiovascular disease Annu Rev Med 2002 53 245 267 11818473
   PubMed Web of Science ®Google Scholar
• Muntner P He J Chen J Fonseca V Whelton PK Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III) Ann Epidemiol 2004 14 9 686 695 15380800
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes 2014 Diabetes Care 2014 37 Suppl 1 S14 S80 24357209
   PubMed Web of Science ®Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement – executive summary Endocr Pract 2013 19 3 536 557 23816937
   PubMed Web of Science ®Google Scholar
• Rydén L Grant PJ Anker SD ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) Eur Heart J 2013 34 39 3035 3087 23996285
   PubMed Web of Science ®Google Scholar
• Bogers RP Bemelmans WJ Hoogenveen RT Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons Arch Intern Med 2007 167 16 1720 1728 17846390
   PubMedGoogle Scholar
• Chan JM Rimm EB Colditz GA Stampfer MJ Willett WC Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men Diabetes Care 1994 17 9 961 969 7988316
   PubMed Web of Science ®Google Scholar
• Colditz GA Willett WC Rotnitzky A Manson JE Weight gain as a risk factor for clinical diabetes mellitus in women Ann Intern Med 1995 122 7 481 486 7872581
   PubMed Web of Science ®Google Scholar
• Shoelson SE Lee J Goldfine AB Inflammation and insulin resistance J Clin Invest 2006 116 7 1793 1801 16823477
   PubMed Web of Science ®Google Scholar
• Donath MY Shoelson SE Type 2 diabetes as an inflammatory disease Nat Rev Immunol 2011 11 2 98 107 21233852
   PubMed Web of Science ®Google Scholar
• Wing RR Bolin P Brancati FL Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes N Engl J Med 2013 369 2 145 154 23796131
   PubMed Web of Science ®Google Scholar
• Gerstein HC Do lifestyle changes reduce serious outcomes in diabetes? N Engl J Med 2013 369 2 189 190 23796132
   PubMed Web of Science ®Google Scholar
• Phelan S Kanaya AM Subak LL Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial J Urol 2012 187 3 939 944 22264468
   PubMed Web of Science ®Google Scholar
• Foster GD Borradaile KE Sanders MH A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study Arch Intern Med 2009 169 17 1619 1626 19786682
   PubMedGoogle Scholar
• Faulconbridge LF Wadden TA Rubin RR One-year changes in symptoms of depression and weight in overweight/obese individuals with type 2 diabetes in the Look AHEAD study Obesity (Silver Spring) 2012 20 4 783 793 22016099
   PubMed Web of Science ®Google Scholar
• Williamson DA Rejeski J Lang W Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes Arch Intern Med 2009 169 2 163 171 19171813
   PubMedGoogle Scholar
• Foy CG Lewis CE Hairston KG Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD trial Obesity (Silver Spring) 2011 19 1 83 93 20559303
   PubMed Web of Science ®Google Scholar
• Rejeski WJ Ip EH Bertoni AG Lifestyle change and mobility in obese adults with type 2 diabetes N Engl J Med 2012 366 13 1209 1217 22455415
   PubMed Web of Science ®Google Scholar
• Ikramuddin S Korner J Lee WJ Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial JAMA 2013 309 21 2240 2249 23736733
   PubMed Web of Science ®Google Scholar
• Schauer PR Kashyap SR Wolski K Bariatric surgery versus intensive medical therapy in obese patients with diabetes N Engl J Med 2012 366 17 1567 1576 22449319
   PubMed Web of Science ®Google Scholar
• Mingrone G Panunzi S De Gaetano A Bariatric surgery versus conventional medical therapy for type 2 diabetes N Engl J Med 2012 366 17 1577 1585 22449317
   PubMed Web of Science ®Google Scholar
• Dorman RB Serrot FJ Miller CJ Case-matched outcomes in bariatric surgery for treatment of type 2 diabetes in the morbidly obese patient Ann Surg 2012 255 2 287 293 21975321
   PubMed Web of Science ®Google Scholar
• Buchwald H Estok R Fahrbach K Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis Am J Med 2009 122 3 248 256.e245 19272486
   PubMed Web of Science ®Google Scholar
• Dixon JB O’Brien PE Playfair J Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial JAMA 2008 299 3 316 323 18212316
   PubMed Web of Science ®Google Scholar
• Cohen RV Pinheiro JC Schiavon CA Salles JE Wajchenberg BL Cummings DE Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity Diabetes Care 2012 35 7 1420 1428 22723580
   PubMed Web of Science ®Google Scholar
• Mingrone G Castagneto-Gissey L Type 2 diabetes mellitus in 2013: a central role of the gut in glucose homeostasis Nat Rev Endocrinol 2014 10 2 73 74 24322651
   PubMed Web of Science ®Google Scholar
• Sjöström L Peltonen M Jacobson P Bariatric surgery and long-term cardiovascular events JAMA 2012 307 1 56 65 22215166
   PubMed Web of Science ®Google Scholar
• Sjöström L Narbro K Sjöström CD Effects of bariatric surgery on mortality in Swedish obese subjects N Engl J Med 2007 357 8 741 752 17715408
   PubMed Web of Science ®Google Scholar
• Stewart KJ Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health JAMA 2002 288 13 1622 1631 12350193
   PubMed Web of Science ®Google Scholar
• Sluik D Buijsse B Muckelbauer R Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis Arch Intern Med 2012 172 17 1285 1295 22868663
   PubMedGoogle Scholar
• Ford ES DeStefano F Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Findings from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study Am J Epidemiol 1991 133 12 1220 1230 2063830
   PubMed Web of Science ®Google Scholar
• Morrish NJ Stevens LK Fuller JH Jarrett RJ Keen H Risk factors for macrovascular disease in diabetes mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease in Diabetics Diabetologia 1991 34 8 590 594 1936663
   PubMed Web of Science ®Google Scholar
• Turner RC Millns H Neil HA Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 1998 316 7134 823 828 9549452
   PubMed Web of Science ®Google Scholar
• Al-Delaimy WK Manson JE Solomon CG Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus Arch Intern Med 2002 162 3 273 279 11822919
   PubMedGoogle Scholar
• Al-Delaimy WK Willett WC Manson JE Speizer FE Hu FB Smoking and mortality among women with type 2 diabetes: the Nurses’ Health Study cohort Diabetes Care 2001 24 12 2043 2048 11723080
   PubMed Web of Science ®Google Scholar
• Qin R Chen T Lou Q Yu D Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies Int J Cardiol 2013 167 2 342 350 22251416
   PubMed Web of Science ®Google Scholar
• Nilsson PM Cederholm J Eeg-Olofsson K Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register Eur J Cardiovasc Prev Rehabil 2009 16 4 506 512 19561510
   PubMedGoogle Scholar
• Neaton JD Wentworth D Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group Arch Intern Med 1992 152 1 56 64 1728930
   PubMedGoogle Scholar
• Clair C Rigotti NA Porneala B Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes JAMA 2013 309 10 1014 1021 23483176
   PubMed Web of Science ®Google Scholar
• Bornfeldt KE Tabas I Insulin resistance, hyperglycemia, and atherosclerosis Cell Metab 2011 14 5 575 585 22055501
   PubMed Web of Science ®Google Scholar
• Skyler JS Bergenstal R Bonow RO Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Circulation 2009 119 2 351 357 19095622
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993 329 14 977 986 8366922
   PubMed Web of Science ®Google Scholar
• Nathan DM Cleary PA Backlund JY Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 2005 353 25 2643 2653 16371630
   PubMed Web of Science ®Google Scholar
• Genuth SM Backlund JY Bayless M Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC Diabetes 2013 62 10 3561 3569 23520132
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 9131 837 853 9742976
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-Year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• Patel A MacMahon S Chalmers J Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 358 24 2560 2572 18539916
   PubMed Web of Science ®Google Scholar
• Duckworth W Abraira C Moritz T Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 2009 360 2 129 139 19092145
   PubMed Web of Science ®Google Scholar
• Gerstein HC Miller ME Byington RP Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 24 2545 2559 18539917
   PubMed Web of Science ®Google Scholar
• Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007 356 24 2457 2471 17517853
   PubMed Web of Science ®Google Scholar
• Riddle MC More reasons to say goodbye to glyburide J Clin Endocrinol Metab 2010 95 11 4867 4870 21051583
   PubMed Web of Science ®Google Scholar
• Home PD Pocock SJ Beck-Nielsen H Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 2009 373 9681 2125 2135 19501900
   PubMed Web of Science ®Google Scholar
• Mahaffey KW Hafley G Dickerson S Results of a reevaluation of cardiovascular outcomes in the RECORD trial Am Heart J 2013 166 2 240 249.e1 23895806
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Guidance for industry: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes 2008 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Accessed January 8, 2014
   Google Scholar
• Ussher JR Drucker DJ Cardiovascular biology of the incretin system Endocr Rev 2012 33 2 187 215 22323472
   PubMed Web of Science ®Google Scholar
• Green JB The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety Postgrad Med 2012 124 4 54 61 22913894
   PubMed Web of Science ®Google Scholar
• Lorber D GLP-1 receptor agonists: effects on cardiovascular risk reduction Cardiovasc Ther 2013 31 4 238 249 23865382
   PubMed Web of Science ®Google Scholar
• White WB Cannon CP Heller SR Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 2013 369 14 1327 1335 23992602
   PubMed Web of Science ®Google Scholar
• Scirica BM Bhatt DL Braunwald E Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 369 14 1317 1326 23992601
   PubMed Web of Science ®Google Scholar
• Riser Taylor S Harris KB The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus Pharmacotherapy 2013 33 9 984 999 23744749
   PubMed Web of Science ®Google Scholar
• Neal B Perkovic V de Zeeuw D Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – a randomized placebo-controlled trial Am Heart J 2013 166 2 217 223.e11 23895803
   PubMed Web of Science ®Google Scholar
• Rosenstock J Marx N Kahn SE Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial Diab Vasc Dis Res 2013 10 4 289 301 23449634
   PubMed Web of Science ®Google Scholar
• Marso SP Poulter NR Nissen SE Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial Am Heart J 2013 166 5 823 830.e5 24176437
   PubMed Web of Science ®Google Scholar
• Vaccaro O Masulli M Bonora E The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes Diabetes Care 2012 35 12 e82 23173143
   PubMed Web of Science ®Google Scholar
• Punthakee Z Bosch J Dagenais G Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial Diabetologia 2012 55 1 36 45 22038523
   PubMed Web of Science ®Google Scholar
• Lincoff AM Tardif JC Neal B Evaluation of the dual peroxisome proliferator-activated receptor alpha/gamma agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial Am Heart J 2013 166 3 429 434 24016490
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators Gerstein HC Bosch J Basal insulin and cardiovascular and other outcomes in dysglycemia N Engl J Med 2012 367 4 319 328 22686416
   PubMed Web of Science ®Google Scholar
• Chen G McAlister FA Walker RL Hemmelgarn BR Campbell NR Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure Hypertension 2011 57 5 891 897 21403089
   PubMed Web of Science ®Google Scholar
• Sarwar N Gao P Seshasai SR Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet 2010 375 9733 2215 2222 20609967
   PubMed Web of Science ®Google Scholar
• Lewington S Clarke R Qizilbash N Peto R Collins R Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 2002 360 9349 1903 1913 12493255
   PubMed Web of Science ®Google Scholar
• Curb JD Pressel SL Cutler JA Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group JAMA 1996 276 23 1886 1892 8968014
   PubMed Web of Science ®Google Scholar
• Tuomilehto J Rastenyte D Birkenhäger WH Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators N Engl J Med 1999 340 9 677 684 10053176
   PubMed Web of Science ®Google Scholar
• Patel A MacMahon S Chalmers J Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 2007 370 9590 829 840 17765963
   PubMed Web of Science ®Google Scholar
• Hansson L Zanchetti A Carruthers SG Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 1998 351 9118 1755 1762 9635947
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group BMJ 1998 317 7160 703 713 9732337
   PubMed Web of Science ®Google Scholar
• Schrier RW Estacio RO Esler A Mehler P Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney Int 2002 61 3 1086 1097 11849464
   PubMed Web of Science ®Google Scholar
• Rutter MK Nesto RW Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care Eur Heart J 2011 32 18 2247 2255 21705358
   PubMed Web of Science ®Google Scholar
• Reboldi G Gentile G Angeli F Ambrosio G Mancia G Verdecchia P Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients J Hypertens 2011 29 7 1253 1269 21505352
   PubMed Web of Science ®Google Scholar
• Arguedas JA Perez MI Wright JM Treatment blood pressure targets for hypertension Cochrane Database Syst Rev 2009 3 CD004349 19588353
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoff RM Gong Y Handberg EM Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease JAMA 2010 304 1 61 68 20606150
   PubMed Web of Science ®Google Scholar
• Bangalore S Kumar S Lobach I Messerli FH Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials Circulation 2011 123 24 2799 2810 21632497
   PubMed Web of Science ®Google Scholar
• Sleight P Redon J Verdecchia P Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study J Hypertens 2009 27 7 1360 1369 19506526
   PubMed Web of Science ®Google Scholar
• Redon J Mancia G Sleight P Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) J Am Coll Cardiol 2012 59 1 74 83 22192672
   PubMed Web of Science ®Google Scholar
• Mancia G Fagard R Narkiewicz K 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 2013 31 7 1281 1357 23817082
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation Global Guideline for Type 2 Diabetes Brussels IDF 2012
   Google Scholar
• Chobanian AV Bakris GL Black HR Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 2003 42 6 1206 1252 14656957
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 2002 288 23 2981 2997 12479763
   PubMed Web of Science ®Google Scholar
• Tatti P Pahor M Byington RP Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM Diabetes Care 1998 21 4 597 603 9571349
   PubMed Web of Science ®Google Scholar
• Estacio RO Jeffers BW Hiatt WR Biggerstaff SL Gifford N Schrier RW The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension N Engl J Med 1998 338 10 645 652 9486993
   PubMed Web of Science ®Google Scholar
• Lindholm LH Hansson L Ekbom T Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group J Hypertens 2000 18 11 1671 1675 11081782
   PubMed Web of Science ®Google Scholar
• Niskanen L Hedner T Hansson L Lanke J Niklason A Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project Diabetes Care 2001 24 12 2091 2096 11723089
   PubMed Web of Science ®Google Scholar
• Lindholm LH Ibsen H Dahlöf B Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 2002 359 9311 1004 1010 11937179
   PubMed Web of Science ®Google Scholar
• McMurray JJ Ostergren J Swedberg K Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 2003 362 9386 767 771 13678869
   PubMed Web of Science ®Google Scholar
• Pfeffer MA Swedberg K Granger CB Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 2003 362 9386 759 766 13678868
   PubMed Web of Science ®Google Scholar
• Granger CB McMurray JJ Yusuf S Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 2003 362 9386 772 776 13678870
   PubMed Web of Science ®Google Scholar
• Schrier RW Estacio RO Mehler PS Hiatt WR Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial Nat Clin Pract Nephrol 2007 3 8 428 438 17653121
   PubMedGoogle Scholar
• ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 2008 358 15 1547 1559 18378520
   PubMed Web of Science ®Google Scholar
• Jamerson K Weber MA Bakris GL Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 2008 359 23 2417 2428 19052124
   PubMed Web of Science ®Google Scholar
• Aksnes TA Skårn SN Kjeldsen SE Treatment of hypertension in diabetes: what is the best therapeutic option? Expert Rev Cardiovasc Ther 2012 10 6 727 734 22894629
   PubMedGoogle Scholar
• Reboldi G Gentile G Angeli F Verdecchia P Optimal therapy in hypertensive subjects with diabetes mellitus Curr Atheroscler Rep 2011 13 2 176 185 21234720
   PubMed Web of Science ®Google Scholar
• Turnbull F Neal B Algert C Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials Arch Intern Med 2005 165 12 1410 1419 15983291
   PubMedGoogle Scholar
• Krentz AJ Lipoprotein abnormalities and their consequences for patients with type 2 diabetes Diabetes Obes Metab 2003 5 Suppl 1 S19 S27 14984018
   PubMed Web of Science ®Google Scholar
• Mooradian AD Dyslipidemia in type 2 diabetes mellitus Nat Clin Pract Endocrinol Metab 2009 5 3 150 159 19229235
   PubMedGoogle Scholar
• Colhoun HM Betteridge DJ Durrington PN Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 2004 364 9435 685 696 15325833
   PubMed Web of Science ®Google Scholar
• Collins R Armitage J Parish S Sleigh P Peto R MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 2003 361 9374 2005 2016 12814710
   PubMed Web of Science ®Google Scholar
• Goldberg RB Mellies MJ Sacks FM Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators Circulation 1998 98 23 2513 2519 9843456
   PubMed Web of Science ®Google Scholar
• Kearney PM Blackwell L Collins R Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 2008 371 9607 117 125 18191683
   PubMed Web of Science ®Google Scholar
• Pyorala K Pedersen TR Kjekshus J Faergeman O Olsson AG Thorgeirsson G Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 1997 20 4 614 620 9096989
   PubMed Web of Science ®Google Scholar
• Sever PS Poulter NR Dahlöf B Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA) Diabetes Care 2005 28 5 1151 1157 15855581
   PubMed Web of Science ®Google Scholar
• Shepherd J Barter P Carmena R Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study Diabetes Care 2006 29 6 1220 1226 16731999
   PubMed Web of Science ®Google Scholar
• Briel M Ferreira-Gonzalez I You JJ Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis BMJ 2009 338 b92 19221140
   PubMed Web of Science ®Google Scholar
• Singh IM Shishehbor MH Ansell BJ High-density lipoprotein as a therapeutic target: a systematic review JAMA 2007 298 7 786 798 17699012
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 2010 362 17 1563 1574 20228404
   PubMed Web of Science ®Google Scholar
• Aim-High Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 2011 365 24 2255 2267 22085343
   PubMed Web of Science ®Google Scholar
• Schwartz GG Olsson AG Abt M Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 2012 367 22 2089 2099 23126252
   PubMed Web of Science ®Google Scholar
• Miller M Stone NJ Ballantyne C Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 2011 123 20 2292 2333 21502576
   PubMed Web of Science ®Google Scholar
• Grundy SM Cleeman JI Merz CN Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 2004 110 2 227 239 15249516
   PubMed Web of Science ®Google Scholar
• Wong ND Patao C Wong K Malik S Franklin SS Iloeje U Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status Diab Vasc Dis Res 2013 10 6 505 513 23975724
   PubMed Web of Science ®Google Scholar
• Ford ES Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: findings from the National Health and Nutrition Examination Survey 1999–2008 J Diabetes 2011 3 4 337 347 21767347
   PubMed Web of Science ®Google Scholar
• Alzahrani SH Ajjan RA Coagulation and fibrinolysis in diabetes Diab Vasc Dis Res 2010 7 4 260 273 20847109
   PubMed Web of Science ®Google Scholar
• Ferreiro JL Gómez-Hospital JA Angiolillo DJ Platelet abnormalities in diabetes mellitus Diab Vasc Dis Res 2010 7 4 251 259 20921090
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists’ Collaboration Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 1994 308 6921 81 106 8298418
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 2002 324 7329 71 86 11786451
   PubMed Web of Science ®Google Scholar
• ETDRS Investigators Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14 JAMA 1992 268 10 1292 1300 1507375
   PubMed Web of Science ®Google Scholar
• Belch J MacCuish A Campbell I The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 2008 337 a1840 18927173
   PubMed Web of Science ®Google Scholar
• Ogawa H Nakayama M Morimoto T Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 2008 300 18 2134 2141 18997198
   PubMed Web of Science ®Google Scholar
• Pignone M Alberts MJ Colwell JA Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation Diabetes Care 2010 33 6 1395 1402 20508233
   PubMed Web of Science ®Google Scholar
• Baigent C Blackwell L Collins R Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 2009 373 9678 1849 1860 19482214
   PubMed Web of Science ®Google Scholar
• De Berardis G Sacco M Strippoli GF Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials BMJ 2009 339 b4531 19897665
   PubMed Web of Science ®Google Scholar
• Zhang C Sun A Zhang P Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis Diabetes Res Clin Pract 2010 87 2 211 218 19853947
   PubMed Web of Science ®Google Scholar
• Calvin AD Aggarwal NR Murad MH Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes Diabetes Care 2009 32 12 2300 2306 19741185
   PubMed Web of Science ®Google Scholar
• Butalia S Leung AA Ghali WA Rabi DM Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis Cardiovasc Diabetol 2011 10 25 21453547
   PubMed Web of Science ®Google Scholar
• De Berardis G Sacco M Evangelista V Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins Trials 2007 8 21 17725825
   PubMed Web of Science ®Google Scholar
• Bhatt DL Marso SP Hirsch AT Ringleb PA Hacke W Topol EJ Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus Am J Cardiol 2002 90 6 625 628 12231089
   PubMed Web of Science ®Google Scholar
• Patrono C Andreotti F Arnesen H Antiplatelet agents for the treatment and prevention of atherothrombosis Eur Heart J 2011 32 23 2922 2932 22019823
   PubMed Web of Science ®Google Scholar
• Hall HM Banerjee S McGuire DK Variability of clopidogrel response in patients with type 2 diabetes mellitus Diab Vasc Dis Res 2011 8 4 245 253 21933840
   PubMed Web of Science ®Google Scholar
• Wiviott SD Braunwald E McCabe CH Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 2007 357 20 2001 2015 17982182
   PubMed Web of Science ®Google Scholar
• Wiviott SD Braunwald E Angiolillo DJ Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – Thrombolysis in Myocardial Infarction 38 Circulation 2008 118 16 1626 1636 18757948
   PubMed Web of Science ®Google Scholar
• Roe MT Armstrong PW Fox KA Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 2012 367 14 1297 1309 22920930
   PubMed Web of Science ®Google Scholar
• Wallentin L Becker RC Budaj A Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 2009 361 11 1045 1057 19717846
   PubMed Web of Science ®Google Scholar
• James S Angiolillo DJ Cornel JH Ticagrelor vs clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial Eur Heart J 2010 31 24 3006 3016 20802246
   PubMed Web of Science ®Google Scholar
• Alexopoulos D Xanthopoulou I Mavronasiou E Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes Diabetes Care 2013 36 8 2211 2216 23491524
   PubMed Web of Science ®Google Scholar
• Sankyo Daiichi Lilly Eli Effient (prasugrel) tablets [package insert] 2009 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022307s002lbl.pdf Accessed January 8, 2014
   Google Scholar
• AstraZeneca Brilinta^®(ticagrelor) tablets [package insert] 2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022433s008lbl.pdf Accessed January 8, 2014
   Google Scholar
• Gaede P Vedel P Larsen N Jensen GV Parving HH Pedersen O Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 2003 348 5 383 393 12556541
   PubMed Web of Science ®Google Scholar
• Gaede P Pedersen O Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis Diabetes 2004 53 Suppl 3 S39 S47 15561920
   PubMed Web of Science ®Google Scholar
• Gaede P Lund-Andersen H Parving HH Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 2008 358 6 580 591 18256393
   PubMed Web of Science ®Google Scholar
• Vaccaro O Franzini L Miccoli R Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year interim analysis of the MIND.IT study: a cluster randomized trial Diabetes Care 2013 36 9 2566 2572 23863908
   PubMed Web of Science ®Google Scholar